Bevacizumab-induced nasal septal perforation: Incidence of symptomatic, confirmed event(s) in colorectal cancer patients

Author： Ramiscal Judi Anne B. Jatoi Aminah

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.4, 2011-05, pp. : 578-581

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer

By Saif Muhammad Elfiky Aymen Salem Ronald

Annals of Surgical Oncology, Vol. 14, Iss. 6, 2007-06 ,pp. : 1860-1869

Springer Publishing Company

Access to resources Recommend Favorite

Nasal septum perforation and bevacizumab

By Power Derek

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 89-93

Humana Press, Inc

Access to resources Recommend Favorite

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients

By Rieger Johannes Bähr Oliver Müller Klaus Franz Kea Steinbach Joachim Hattingen Elke

Journal of Neuro-Oncology, Vol. 99, Iss. 1, 2010-08 ,pp. : 49-56

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer

By Kusaba Hitoshi Esaki Taito Kishimoto Junji Uchino Keita Arita Shuji Kumagai Hozumi Mitsugi Kenji Akashi Koichi Baba Eishi

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 29-34

Springer Publishing Company

Access to resources Recommend Favorite

A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer

By Petrelli Fausto

Breast Cancer, Vol. 18, Iss. 3, 2011-07 ,pp. : 226-230

Springer Publishing Company

Access to resources Recommend Favorite